Physician profile
Priya Patel
NPI 1467940734
$6,558.50
in general payments reported to CMS, 2019-2025
35 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $13.41 · 2021: $281 · 2022: $299 · 2023: $572 · 2024: $2,683 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,533 · Education: $93.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,532.55 |
| Education | $93.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,307.84 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $765.82 | 2021-2025 | Dupixent |
| Amgen INC. | $639.26 | 2023-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $565.90 | 2024-2025 | |
| Glaxosmithkline, LLC. | $464.16 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $356.74 | 2023-2025 | |
| Csl Behring | $346.33 | 2021-2025 | Andembry, Hizentra, Haegarda |
| Abbvie INC. | $221.85 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $180.07 | 2025 | Neffy |
| Pfizer INC. | $152.63 | 2024 | |
| Genentech USA, INC. | $148.50 | 2024-2025 | Xolair |
| Biocryst US Sales Co., LLC | $138.34 | 2024-2025 | Orladeyo |
| Grifols USA, LLC | $104.20 | 2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $99.56 | 2024-2025 | Eohilia, Glassia |
| Mallinckrodt Enterprises LLC | $97.06 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.77 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $73.15 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $55.67 | 2023-2024 | Yupelri |
| Philips North America LLC | $54.09 | 2023-2024 | (Ak6) Vest Therapy |
| Leo Pharma INC. | $50.76 | 2025 | Adbry |
| Lilly USA, LLC | $49.09 | 2025 | Ebglyss |
| Aytu Biopharma, INC. | $48.99 | 2024-2025 | Karbinal |
| Octapharma USA, INC. | $46.26 | 2023-2024 | Cutaquig |
| Ionis Pharmaceuticals, INC. | $45.98 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $44.92 | 2024 | Ruconest |
| Hikma Pharmaceuticals USA | $34.43 | 2024-2025 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $32.53 | 2025 | Xhance, Nuzyra |
| Optinose US, INC. | $32.41 | 2025 | |
| Kaleo, INC. | $31.77 | 2023-2024 | Auvi-Q |
| Incyte Corporation | $29.61 | 2025 | Opzelura |
| Horizon Therapeutics Plc | $24.11 | 2023 | Actimmune |
| Cycle Pharmaceuticals INC | $23.77 | 2025 | Sajazir |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.01 | 2021 | |
| Galderma Laboratories, L.P. | $17.67 | 2025 | Nemluvio |
| Novo Nordisk INC | $13.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.